Adult Medulloblastoma: Updates on Current Management and Future Perspectives

Area of Science:

• Neuro-oncology
• Pediatric and Adult Oncology
• Clinical Neurology

Background:

• Medulloblastoma (MB) is a malignant embryonal tumor of the posterior fossa, often affecting pediatric patients but also occurring in 14-30% of adults under 40.
• Adult MB incidence is low (0.6 per million), representing a small fraction of adult nervous system tumors (0.4-1%).
• Limited prospective trials exist for adult MB, leading to treatment extrapolation from pediatric protocols, raising questions about applicability.

Purpose of the Study:

• To review the current management strategies for adult medulloblastoma.
• To highlight the distinct molecular and clinical characteristics of adult MB compared to pediatric MB.
• To assess the effectiveness of different treatment modalities in adult MB patients.

Main Methods:

• Review of recent published literature on adult medulloblastoma management.
• Focus on upfront chemotherapy effectiveness.
• Analysis of targeted therapy development and reduced radiotherapy roles.

Main Results:

• Adult medulloblastoma presents unique molecular and clinical features compared to pediatric cases.
• Current treatment paradigms are largely adapted from pediatric protocols, with uncertain efficacy in adults.
• Emerging research explores upfront chemotherapy, targeted therapies, and dose-reduced radiotherapy for adult MB.

Conclusions:

• Adult medulloblastoma requires tailored treatment approaches distinct from pediatric protocols.
• Further research and dedicated clinical trials are crucial for optimizing adult MB management.
• Investigating upfront chemotherapy, targeted agents, and modified radiotherapy is essential for improving outcomes.